|
MUT expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
2.038300E-04 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.63025148935958E-12 |
| Stage1-vs-Stage2 |
3.752200E-02 |
| Stage1-vs-Stage3 |
1.065020E-01 |
| Stage1-vs-Stage4 |
1.119810E-02 |
| Stage2-vs-Stage3 |
5.502100E-03 |
| Stage2-vs-Stage4 |
1.021790E-03 |
| Stage3-vs-Stage4 |
3.704800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.34290000014725E-07 |
| Normal-vs-Asian |
4.53490023311076E-10 |
| Caucasian-vs-AfricanAmerican |
6.018000E-01 |
| Caucasian-vs-Asian |
8.344800E-01 |
| AfricanAmerican-vs-Asian |
7.477600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
1.316990E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62558855265615E-12 |
| Normal-vs-Age(41-60Yrs) |
3.33066907387547E-16 |
| Normal-vs-Age(61-80Yrs) |
2.57860399699439E-12 |
| Normal-vs-Age(81-100Yrs) |
2.360800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.780800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.706800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.986000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.888800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.454400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.518800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.614500E-02 |
| Classical-VS-Follicular |
1.289450E-01 |
| Classical-VS-Other |
2.956400E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
7.161700E-03 |
| Tall-VS-Other |
8.047400E-01 |
| Tall-VS-Normal |
1.69164682262135E-12 |
| Follicular-VS-Other |
1.956400E-01 |
| Follicular-VS-Normal |
6.49010000186578E-08 |
| Other-VS-Normal |
1.411800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.50830475781549E-14 |
| Normal-vs-N1 |
4.32986979603811E-15 |
| N0-vs-N1 |
1.176100E-02 |
|
|
